Financial reports
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
25 Apr 24
8-K
Results of Operations and Financial Condition
22 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 Jan 24
8-K
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
29 Jan 24
8-K
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
21 Dec 23
8-K
Departure of Directors or Certain Officers
1 Dec 23
8-K
Results of Operations and Financial Condition
9 Nov 23
8-K
Departure of Directors or Certain Officers
20 Oct 23
8-K
HOOKIPA announces executive leadership change
13 Sep 23
8-K
Results of Operations and Financial Condition
10 Aug 23
Registration and prospectus
S-3
Shelf registration
22 Dec 23
SC TO-I/A
Issuer tender offer statement (amended)
12 Sep 23
SC TO-I
Issuer tender offer statement
10 Aug 23
424B5
Prospectus supplement for primary offering
1 Jun 23
S-8
Registration of securities for employees
13 Apr 23
S-3
Shelf registration
12 Jul 22
S-3
Shelf registration
11 Jul 22
S-8
Registration of securities for employees
29 Apr 22
424B5
Prospectus supplement for primary offering
2 Mar 22
424B5
Prospectus supplement for primary offering
1 Mar 22
Proxies
PRE 14A
Preliminary proxy
16 Apr 24
DEF 14A
Definitive proxy
13 Apr 23
DEFA14A
Additional proxy soliciting materials
16 May 22
DEF 14A
Definitive proxy
16 May 22
PRE 14A
Preliminary proxy
2 May 22
DEF 14A
Definitive proxy
20 Apr 21
DEFA14A
Additional proxy soliciting materials
20 Apr 21
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
Other
EFFECT
Notice of effectiveness
5 Jan 24
CORRESP
Correspondence with SEC
2 Jan 24
UPLOAD
Letter from SEC
29 Dec 23
EFFECT
Notice of effectiveness
22 Jul 22
CORRESP
Correspondence with SEC
19 Jul 22
EFFECT
Notice of effectiveness
18 Jul 22
UPLOAD
Letter from SEC
14 Jul 22
CORRESP
Correspondence with SEC
13 Jul 22
UPLOAD
Letter from SEC
13 Jul 22
UPLOAD
Letter from SEC
29 May 20
Ownership
4
Klaus Orlinger
17 Apr 24
4
Jorn Aldag
17 Apr 24
4
Mark Winderlich
17 Apr 24
4
Reinhard Kandera
17 Apr 24
4
Roman Necina
17 Apr 24
3
Mark Winderlich
11 Apr 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
GILEAD SCIENCES, INC.
22 Dec 23